- Company
- Flu drug prescription plummets by 21% due to COVID-19
- by Kim, Jin-Gu Apr 28, 2020 06:23am
- The general prescription volume of influenza medications treatment has gone down drastically. Compared to the previous season, this season’s volume has plummeted by 21.0 percent. The flu treatment prescription seems to have been affected by the COVID-19 outbreak. The threat of the virus has particularly raised the awareness of personal hygi
- Company
- Rx amount for Ezetimibe·Statin increased 5 times in 4 years
- by Chon, Seung-Hyun Apr 28, 2020 06:23am
- The combination of Statin and Ezetimibe in the hyperlipidemic drug market is rapidly increasing. Over the past four years, outpatient prescription amount has increased five times. It was prescribed more than &8361;100 billion in the first quarter. The prescription scale of the combination of 'Rosuvastatin·Ezetimibe' such as Hanmi's 'Rosuzet
- Company
- Xarelto-Eliquis follow Lixiana dominating NOAC market
- by Kim, Jin-Gu Apr 27, 2020 06:11am
- Lixiana has reaffirmed its dominance in the non-vitamin K antagonist oral anticoagulant (NOAC) market. Eliquis has gotten close to taking over the second place from Xarelto with ever more intense competition in the market,. First released in last June, generic products of Eliquis are expanding their pies. Currently, 12 products are released
- Company
- “Considering treatment options for ankylosing spondylitis”
- by Eo, Yun-Ho Apr 27, 2020 06:10am
- In the autoimmune disease area, where tumor necrosis factor alpha (TNF alpha) inhibitor is leading the prescription market, various options of oral Janus kinase (JAK) inhibitors have been released so far. Guidelines on treating ankylosing spondylitis and spondylarthritis in Korea and other countries have a tendency to emphasize starting
- Company
- Keytruda to finally get Cancer Committee nod after 2years?
- by Eo, Yun-Ho Apr 24, 2020 06:27am
- After waiting for two long years, MSD is committed to receive the Korean health authority’s approval on Keytruda’s coverage expansion this time. According to pharmaceutical industry sources, the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee’s deliberation on Keytruda (pembrolizumab) has been schedu
- Company
- The KPBMA promotes of co-development of COVID-19 treatments
- by Lee, Seok-Jun Apr 24, 2020 06:26am
- The KPBMA promotes joint development of COVID-19 treatment. This is the first 'co-investment and joint development' method among member companies. The KPBMA held a board of directors meeting on the 21st to discuss this. Participants decided to aggregate their competencies at the industrial level, not individual companies, based on the p
- Company
- Amid COVID-19, March drug export hits record high
- by Kim, Jin-Gu Apr 24, 2020 06:26am
- A monthly export volume of Korean pharmaceuticals has reached a record high in last March. Sources view the COVID-19 outbreak has not affected the pharmaceutical production and export significantly. According to the import and export statistics data published by Korea Customs Service (KCS), Korea has exported USD 538.09 million (approximatel
- Company
- General hospitals to prescribe obesity drug Qsymia
- by Eo, Yun-Ho Apr 23, 2020 06:27am
- Gaining popularity in the obesity treatment market, Qsymia has entered its prescription code in Korean general hospitals. According to pharmaceutical industry, Qsymia (phentermine hydrochloride plus topiramate), co-marketed by Alvogen Korea and Chong Kun Dang, has been recently passed by Drug Committees at the Big Fives including Severan
- Company
- Global companies made KRW 21M per employee last year
- by An, Kyung-Jin Apr 23, 2020 06:26am
- Korea Otsuka Pharmaceutical has generated the highest operating profit per employee last year among Korean branches of multinational pharmaceutical companies. Each employee at the multinational company has made 108 million won worth of operating profit. On Apr. 21, an analysis on 30 multinational pharmaceutical companies in Korea surveyed
- Company
- COVID-19 hinders Italian API distribution causing stock-out
- by Jung, Hye-Jin Apr 22, 2020 06:03am
- Due to temporary suspension of active pharmaceutical ingredient (API) distribution amid COVID-19 pandemic, many drugs have been reportedly sold out. The industry experts see that the restricted international logistics of human and material resources during the pandemic has affected a number of drugs to be stocked out for a long and shor
